Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus
- PMID: 22973869
- DOI: 10.1111/j.1464-410X.2012.11498.x
Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus
Abstract
What's known on the subject? and What does the study add? In patients with pRCC, the presence of venous tumour thrombus is known to be a predictor of poorer outcomes. However, a paucity of data is available regarding the prognostic significance of histology in patients with RCC and IVC thrombus. In our series, we found that patients with type II pRCC had significantly poorer outcomes when compared to those with cRCC. Although the lack of effective treatment for patients with metastatic pRCC may have contributed to these adverse outcomes, type II papillary histology was independent predictor not only of CSS but also of RFS.
Objective: • To analyze the prognostic impact of papillary histology on oncological outcomes in patients with renal cell carcinoma (RCC) and inferior vena cava (IVC) thrombus.
Patients and methods: • We reviewed the medical records of 74 patients who underwent radical nephrectomy and IVC thrombectomy between 1990 and 2010 for clear cell or papillary RCC. • We compared the clinicopathological features and clinical outcomes of 62 patients with clear cell RCC (cRCC) and 12 with papillary RCC (pRCC). • All cases of pRCC were subdivided into type I or type II. • The prognostic role of papillary histology on recurrence-free survival (RFS) and cancer-specific survival (CSS) was estimated using Cox's regression models.
Results: • Upon reclassification of the pRCC subtype, all 12 patients with pRCC had type II tumours. • Patients with type II pRCC were significantly younger (P=0.028) and were more probably women (P=0.025) than those with cRCC • The 2- and 5-year CSS rates were 81.1% and 53.6% in cRCC patients, and 28.1% and 0% in type II pRCC patients, respectively. All eight patients with non-metastatic type II pRCC developed disease recurrence at a median interval of 6 months after surgery, whereas 25 of 44 (56.8%) patients with non-metastatic cRCC experienced such recurrence at a median interval of 10 months after surgery. • Patients with type II pRCC showed significantly lower CSS (P<0.001) and RFS (P=0.002) than those with cRCC. • On multivariate analysis, type II papillary histology was an independent predictor of CSS (hazard ratio, 3.73; P=0.003) and RFS (hazard ratio, 3.15; P=0.015).
Conclusions: • Type II papillary histology appears to be predominant in cases of pRCC with IVC thrombus. • Patients with type II pRCC who presented with IVC thrombus had significantly worse outcomes than those with cRCC, and histology is an important prognostic factor in patients with RCC and IVC thrombus.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.
Comment in
-
Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.BJU Int. 2012 Dec;110(11 Pt B):E679. doi: 10.1111/j.1464-410X.2012.11510.x. Epub 2012 Sep 14. BJU Int. 2012. PMID: 22973898 No abstract available.
Similar articles
-
Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.BJU Int. 2012 Dec;110(11 Pt B):E470-4. doi: 10.1111/j.1464-410X.2012.11155.x. Epub 2012 Apr 23. BJU Int. 2012. PMID: 22519938
-
Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.Eur Urol. 2014 Sep;66(3):577-83. doi: 10.1016/j.eururo.2013.06.048. Epub 2013 Jul 10. Eur Urol. 2014. PMID: 23871402
-
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1. BJU Int. 2012. PMID: 22044519
-
Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus.BJU Int. 2012 Oct;110(7):926-39. doi: 10.1111/j.1464-410X.2012.11174.x. Epub 2012 Apr 30. BJU Int. 2012. PMID: 22540179 Review.
-
[Diagnosis and surgical management of renal cell carcinoma with inferior vena cava tumor thrombus--a report of 6 cases with literature review].Ai Zheng. 2005 Nov;24(11):1394-7. Ai Zheng. 2005. PMID: 16552970 Review. Chinese.
Cited by
-
Oncologic Outcomes and Predictors in Patients with Stage PT3aNxM0 Renal Cell Carcinoma Following Radical Nephrectomy.Urol Res Pract. 2023 Jan;49(1):25-32. doi: 10.5152/tud.2023.22072. Urol Res Pract. 2023. PMID: 37877835 Free PMC article.
-
Preoperative Gamma-Glutamyltransferase Is Associated with Cancer-Specific Survival and Recurrence-Free Survival of Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.Biomed Res Int. 2017;2017:3142926. doi: 10.1155/2017/3142926. Epub 2017 Jan 11. Biomed Res Int. 2017. PMID: 28168196 Free PMC article.
-
Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).Curr Urol Rep. 2014 May;15(5):404. doi: 10.1007/s11934-014-0404-7. Curr Urol Rep. 2014. PMID: 24682884 Review.
-
Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis.Transl Androl Urol. 2021 Aug;10(8):3255-3266. doi: 10.21037/tau-21-329. Transl Androl Urol. 2021. PMID: 34532250 Free PMC article.
-
Clinicopathological Features of Papillary Renal Cell Carcinoma With Venous Tumor Thrombus: Case Series from a Large Chinese Center.Clin Med Insights Oncol. 2022 Apr 17;16:11795549221092217. doi: 10.1177/11795549221092217. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 35465470 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical